Status:

Red

Decision Date:

September 2019

Comments

RED:

• NICE TA596 - treatment of moderate-to-severe plaque psoriasis
• NICE TA803 - Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs. (Decision date - August 2022)
• NICE TA888 - Risankizumab for previously treated moderately to severely active Crohn's disease. (Decision date - June 2023)

ICB commissioned 

search again